Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Steins

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Clinical Lung Cancer|January 27, 2018
Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other IndicesDenise Bernhardt, Laila König, Sophie Aufderstrasse, et al.
Plos One|September 27, 2017
CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutationJing Zhao, Julien Dinkel, Arne Warth, et al.
Trials|July 18, 2018
Whole brain radiation therapy alone versus radiosurgery for patients with 1-10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trialDenise Bernhardt, Adriane Hommertgen, Daniela Schmitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.
The New England Journal of Medicine|September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerHossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical Lung Cancer|January 27, 2018
Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other IndicesDenise Bernhardt, Laila König, Sophie Aufderstrasse, et al.
Plos One|September 27, 2017
CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutationJing Zhao, Julien Dinkel, Arne Warth, et al.
Trials|July 18, 2018
Whole brain radiation therapy alone versus radiosurgery for patients with 1-10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trialDenise Bernhardt, Adriane Hommertgen, Daniela Schmitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancerJoachim von Pawel, Robert Jotte, David R Spigel, et al.
The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.
The New England Journal of Medicine|September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerHossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
The New England Journal of Medicine|June 22, 2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerDavid P Carbone, Martin Reck, Luis Paz-Ares, et al.
Pageof 3